MR imaging can provide high resolution 3D maps of structural and functional information in vivo yet its use of mapping in vivo gene expression is largely unexplored. The major obstacle to its implementation is the low threshold of (super) paramagnetic label detection. We have developed a strategy that relies on synergistic amplification of biological processes to directly map transgene expression. The basic concept and general method relies on 1) uninhibitable internalizing receptors (e.g. engineered transferrin receptor, ETR) and probing the receptor with affinity ligands (e.g. Tf) containing thousands of iron atoms which increase R2/R2 relaxivity upon cellular internalization. In preliminary feasibility studies we have created cell lines stably expressing ETR and are insensitive to iron-induced down regulation. Using ETR targeted holo-Tf containing iron oxide (Tf-MION), we have furthermore shown that 1) cellular uptake of this probe is specific and inhibitable, 2) cellular accumulation of iron from Tf-MION is more efficient for MR imaging when compared to iron from Tf, 3) that the probe accumulates at significantly higher amounts in ETR+ tumors compared to ETR- tumors and 4) that transgene expression can be visualized in vivo by MR imaging (1.5 T) in live animals and by high resolution MR microscopy (7.1T). With our expertise in constructing viral expression vectors we propose to expand this research to test whether the recombinant ETR system can be used as a universal marker gene for MR imaging of gene expression. The hypotheses underlying these experiments is that ETR gene expression will correlate with expression of therapeutic genes when driven by the same promoter and/or being part of a polycistronic vector. Using novel HSV/EBV amplicons we will test this model system in human tumors xenografted into immunocompromised mice. The long-term goal of this research is to extend the capabilities of MR and apply it to in vivo imaging of gene expression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA085240-05
Application #
6701785
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Menkens, Anne E
Project Start
2000-02-15
Project End
2006-01-31
Budget Start
2004-02-01
Budget End
2006-01-31
Support Year
5
Fiscal Year
2004
Total Cost
$381,895
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Yuan, Hushan; Luo, Ji; Weissleder, Ralph et al. (2006) Wortmannin-C20 conjugates generate wortmannin. J Med Chem 49:740-7
Shinde Patil, Vivek R; Friedrich, Erik B; Wolley, Allison E et al. (2005) Bone marrow-derived lin(-)c-kit(+)Sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. Neoplasia 7:234-40
Allport, Jennifer R; Shinde Patil, Vivek R; Weissleder, Ralph (2004) Murine neuronal progenitor cells are preferentially recruited to tumor vasculature via alpha4-integrin and SDF-1alpha-dependent mechanisms. Cancer Biol Ther 3:838-44
Allport, Jennifer R; Weissleder, Ralph (2003) Murine Lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro. Neoplasia 5:205-17
Hogemann-Savellano, Dagmar; Bos, Erik; Blondet, Cyrille et al. (2003) The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5:495-506
Hogemann, Dagmar; Ntziachristos, Vasilis; Josephson, Lee et al. (2002) High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug Chem 13:116-21
Hogemann, D; Josephson, L; Weissleder, R et al. (2000) Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem 11:941-6